These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 14693309)

  • 1. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension.
    Coca A; Calvo C; Sobrino J; Gómez E; López-Paz JE; Sierra C; Bragulat E; de la Sierra A
    Clin Ther; 2003 Nov; 25(11):2849-64. PubMed ID: 14693309
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trough-to-peak ratio, smoothness index, and circadian blood pressure profile after treatment with once-daily fixed combination of losartan 100 and hydrochlorothiazide 25 in essential hypertension.
    Coca A; Sobrino J; Soler J; Felip A; Pelegrí A; Mínguez A; Vila J; de la Sierra A; Plana J
    J Cardiovasc Pharmacol; 2002 Jun; 39(6):824-33. PubMed ID: 12021576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial.
    Neutel JM; Saunders E; Bakris GL; Cushman WC; Ferdinand KC; Ofili EO; Sowers JR; Weber MA;
    J Clin Hypertens (Greenwich); 2005 Oct; 7(10):578-86. PubMed ID: 16227760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter, randomized, double-blind comparison of the efficacy and safety of irbesartan and enalapril in adults with mild to moderate essential hypertension, as assessed by ambulatory blood pressure monitoring: the MAPAVEL Study (Monitorización Ambulatoria Presión Arterial APROVEL).
    Coca A; Calvo C; García-Puig J; Gil-Extremera B; Aguilera MT; de la Sierra A; Martín-Hidalgo A; Marín R;
    Clin Ther; 2002 Jan; 24(1):126-38. PubMed ID: 11833827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial.
    Ofili EO; Cable G; Neutel JM; Saunders E
    J Womens Health (Larchmt); 2008; 17(6):931-8. PubMed ID: 18681815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
    Lacourcière Y; Neutel JM; Schumacher H
    Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazide combination in lowering blood pressure: a retrospective observational study in Oman.
    Al Balushi KA; Habib JQ; Al-Zakwani I
    Med Princ Pract; 2013; 22(3):265-9. PubMed ID: 23235349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone.
    Rosenstock J; Rossi L; Lin CS; MacNeil D; Osbakken M
    J Clin Pharm Ther; 1998 Dec; 23(6):433-40. PubMed ID: 10048504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the efficacy and safety of irbesartan/hydrochlorothiazide combination therapy with irbesartan monotherapy in the treatment of moderate or severe hypertension in diabetic and obese hypertensive patients: a post-hoc analysis review.
    Neutel JM
    Postgrad Med; 2011 Jul; 123(4):126-34. PubMed ID: 21680997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.
    Ofili EO; Ferdinand KC; Saunders E; Neutel JM; Bakris GL; Cushman WC; Sowers JR; Weber MA
    J Natl Med Assoc; 2006 Apr; 98(4):618-26. PubMed ID: 16623075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations.
    Bobrie G; Delonca J; Moulin C; Giacomino A; Postel-Vinay N; Asmar R;
    Am J Hypertens; 2005 Nov; 18(11):1482-8. PubMed ID: 16280286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase IV, 8-week, multicenter, randomized, active treatment-controlled, parallel group, efficacy, and tolerability study of high-dose candesartan cilexetil combined with hydrochlorothiazide in Korean adults with stage II hypertension.
    Lee HY; Hong BK; Chung WJ; Lee BK; Lee SH; Jeon DW; Ahn YK; Kim D; Park CK; Kim SH; Jung HO; Kim BO; Choi D
    Clin Ther; 2011 Aug; 33(8):1043-56. PubMed ID: 21831438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial.
    Chrysant SG; Neutel JM; Ferdinand KC;
    J Natl Med Assoc; 2009 Apr; 101(4):300-7. PubMed ID: 19397219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-related antihypertensive effects of irbesartan in patients with mild-to-moderate hypertension.
    Pool JL; Guthrie RM; Littlejohn TW; Raskin P; Shephard AM; Weber MA; Weir MR; Wilson TW; Wright J; Kassler-Taub KB; Reeves RA
    Am J Hypertens; 1998 Apr; 11(4 Pt 1):462-70. PubMed ID: 9607385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.
    Oigman W; Gomes MA; Pereira-Barretto AC; Póvoa R; Kohlmann O; Rocha JC; Nobre F
    Clin Ther; 2013 May; 35(5):702-10. PubMed ID: 23623755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
    Guthrie R; Reggi DR; Plesher MM; Saini RK; Battikha JP
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):306-11. PubMed ID: 8722432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: A randomized, double-blind, parallel-group study in primary care.
    Edes I;
    Clin Drug Investig; 2009; 29(5):293-304. PubMed ID: 19366271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.